title: [Antifungal treatments].
abstract: THE SITUATION: Invasive fungal infections are increasing and are associated with high rates of morbidity and mortality. The recent emergence of new molecules and antifungal classes raises the hope of new therapeutic perspectives. SECOND GENERATION TRIAZOLES: Voriconazole, ravuconazole and posaconazole have a broader spectrum than the first generation, including notably Aspergillus species and Candida species, resistant to fluconazole. ECHINOCANDINES: Caspofongine and micafongine belong to a new family of antifungals: echinocandines. With a different mechanism of action, they affect the fungal wall. PRESENT RESEARCHES: Are oriented towards the exploration of prophylaxis in patients at risk and, in particular, towards antifungal combinations. However, regarding the latter, in vitro studies and experiments in animals are rare and sometimes contradicting, and clinical trials are almost inexistent.
authors.affiliation: Service de maladies infectieuses et tropicales CH F. Quesnay, 78200 Mantes-la-Jolie. f.granier@ch-mantes-la-jolie.rss.fr
authors.forename: Françoise
authors.initials: F
authors.lastname: Granier
mesh_terms: D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000517:prevention & control; D012307:Risk Factors
chemical_list: D000935:Antifungal Agents